AbbVie
ABBV
$230.01
+6.25%
AbbVie is a global pharmaceutical company operating in the Drug Manufacturers - General industry, with a core business focused on immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta), neuroscience, and aesthetics (Botox). It is a market leader, particularly in immunology, and has established itself as a diversified healthcare giant through strategic acquisitions like Allergan (2020), Cerevel, and ImmunoGen (2024). The current investor narrative centers on the successful transition from Humira's patent cliff to its next-generation immunology drugs, Skyrizi and Rinvoq, which are driving growth, while recent news highlights pipeline progress in obesity and oncology, alongside navigating competitive and regulatory developments.…
ABBV
AbbVie
$230.01
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: Hold. AbbVie is successfully navigating its post-Humira transition with strong immunology growth and cash flow, but its premium valuation and recent technical weakness warrant caution until earnings normalize to justify the forward multiple. Analyst sentiment is bullish, but the lack of a consensus price target in the data makes the implied upside unclear.
Supporting Evidence: The investment case is supported by a forward P/E of 13.32x, which prices in a substantial earnings recovery from the depressed trailing P/E of 96.41x. Revenue growth of 10.04% YoY is solid, and profitability metrics rebounded strongly in Q4 with an 84.02% gross margin and 34.96% operating margin. The company's $18.70 billion TTM free cash flow provides a strong foundation for its dividend (yield ~2.87%) and continued business development. However, the price-to-sales ratio of 6.65x and EV/EBITDA of 26.70x indicate a valuation premium that requires flawless execution.
Risks & Conditions: The two biggest risks are valuation compression if earnings growth disappoints, and increased competitive pressure in immunology from new entrants. This Hold rating would upgrade to a Buy if the stock sustains a breakout above its 52-week high of $244.81 on confirming volume, signaling the end of the downtrend, or if the forward P/E compresses further toward 11x while growth remains intact. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if the stock breaks decisively below its 52-week low of $181.73. Relative to its own history and the likely premium to mature pharma peers, the stock is fairly valued to slightly overvalued, baking in significant future success.
Sign up to view all
ABBV 12-Month Price Forecast
The outlook for AbbVie is one of transition under pressure. The fundamental story of moving past Humira is working, with immunology driving growth and profitability rebounding. However, the stock's technical weakness and premium sales multiple reflect market skepticism and competitive fears. The base case of range-bound trading is most likely, as the company must prove its forward earnings estimates are achievable over several quarters. The stance would upgrade to bullish on a sustained technical breakout above $245 with volume, confirming the fundamental story is overpowering the negative sentiment. It would turn bearish if the stock loses the $181 support level, signaling a failure of the current narrative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $299.01 and implied upside of +30.0% versus the current price.
Average Target
$299.01
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$184 - $299
Analyst target range
Analyst coverage is robust with 12 analysts providing estimates, indicating strong institutional interest in this large-cap pharmaceutical leader. The consensus sentiment is bullish, as evidenced by recent institutional ratings which include actions like 'Overweight' from Morgan Stanley and Piper Sandler, an upgrade to 'Buy' from HSBC, and a predominance of 'Outperform' or 'Buy' ratings, though some firms maintain a 'Neutral' stance. The average target price is not explicitly provided in the data, but analyst estimates for revenue and EPS are available; the implied upside/downside cannot be calculated without the consensus price target. The target range for estimated EPS is tight, from $19.57 to $20.48, signaling strong conviction in near-term earnings forecasts. The high end of the EPS target range assumes successful execution on growth drivers like Skyrizi and Rinvoq, while the low end likely factors in competitive pressures and pipeline risks. The recent pattern of analyst actions shows a mix of reaffirmations and one upgrade, with no recent downgrades, suggesting a stable to improving sentiment backdrop as the company navigates its post-Humira transition.
Bulls vs Bears: ABBV Investment Factors
The bull case, centered on a successful post-Humira transition led by Skyrizi/Rinvoq growth and strong cash generation, currently holds stronger evidence given the concrete 10% revenue growth and $18.7B FCF. However, the bear case highlights significant valuation and execution risks, with the stock trading at a premium sales multiple while in a technical downtrend. The single most important tension in the investment debate is whether the forward P/E of 13.32x accurately reflects a normalized, high-profitability earnings base, or if the elevated trailing P/E of 96.41x and premium sales multiple signal over-optimism that could lead to multiple compression if growth decelerates or competition intensifies.
Bullish
- Strong Immunology Growth Offsets Humira Decline: Skyrizi and Rinvoq delivered $5.01B and $2.37B respectively in Q4 2025, driving a 10.04% YoY revenue increase to $16.62B. This demonstrates the successful transition from Humira, which has declined to $1.25B.
- Robust Profitability and Cash Generation: Q4 2025 gross margin rebounded to 84.02% and operating margin was 34.96%, indicating a return to normalized profitability. The company generated $18.70B in TTM free cash flow, providing ample capacity for dividends, buybacks, and M&A.
- Attractive Forward Valuation: The forward P/E of 13.32x is significantly lower than the trailing P/E of 96.41x, pricing in a substantial earnings recovery. This forward multiple suggests the market expects normalized, profitable growth.
- Pipeline Progress in Key Areas: Recent news includes positive early obesity drug data (up to 10% weight loss) and strong Phase 3 results for Skyrizi in Crohn's disease (55% remission). These are long-term growth catalysts beyond the current immunology franchise.
Bearish
- Elevated Trailing P/E and Premium Sales Multiple: The trailing P/E of 96.41x is extremely high, and the PS ratio of 6.65x and EV/EBITDA of 26.70x suggest a premium valuation. This leaves little room for error in the anticipated earnings recovery.
- Recent Technical Downtrend and Underperformance: The stock is down 4.55% over 6 months and underperformed the SPY by 9.57% over 3 months. Trading at only 34% of its 52-week range ($181.73 to $244.81) near $216.49 reflects significant selling pressure.
- Increasing Competitive Threats in Core Markets: Recent FDA approval of Johnson & Johnson's oral psoriasis drug Icotyde introduces new competition for Skyrizi. The immunology market remains fiercely contested, potentially pressuring long-term pricing and market share.
- Regulatory and Manufacturing Setbacks: The FDA recently rejected AbbVie's wrinkle drug, TrenibotE, due to manufacturing issues. While not a science failure, such delays create near-term headline risk and highlight execution challenges.
ABBV Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of +16.71% but a 6-month decline of -4.55%, indicating recent weakness. As of the latest close of $216.49, the price is trading at approximately 34% of its 52-week range ($181.73 to $244.81), positioning it much closer to the yearly low, which suggests a potential value opportunity but also reflects significant selling pressure and negative momentum. Recent momentum shows a short-term divergence, with a 1-month gain of +1.28% and a 3-month gain of +5.57%, which contrasts with the negative 6-month performance, hinting at a possible stabilization or nascent recovery attempt from deeply oversold levels, though the stock has underperformed the SPY by -9.57% over the last three months. Key technical levels are clearly defined, with major support at the 52-week low of $181.73 and resistance at the 52-week high of $244.81; a sustained breakdown below support would signal a continuation of the bearish trend, while a breakout above resistance is needed to confirm a new uptrend. The stock's beta of 0.309 indicates it is approximately 69% less volatile than the broader market, which is unusually low for a large-cap pharma and suggests it has acted as a relative safe haven during recent market swings, though its significant max drawdown of -19.23% shows it is not immune to company-specific volatility.
Beta
0.31
0.31x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$182-$245
Price range past year
Annual Return
+24.1%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | -0.2% |
| 3m | +12.1% | +14.0% |
| 6m | +0.1% | +7.8% |
| 1y | +24.1% | +25.3% |
| ytd | +0.3% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth is positive but decelerating; the most recent Q4 2025 revenue was $16.62 billion, representing a year-over-year growth of 10.04%, a significant improvement from the prior quarter's $15.78 billion. Segment data reveals the immunology portfolio is the primary growth driver, with Skyrizi contributing $5.01 billion and Rinvoq $2.37 billion, successfully offsetting the decline of Humira ($1.25 billion). Profitability is strong but volatile; Q4 2025 net income was $1.82 billion with a robust gross margin of 84.02%, a substantial recovery from the prior quarter's net income of $186 million and gross margin of 66.38%. The operating margin for Q4 2025 was a healthy 34.96%, indicating effective cost management and a return to normalized profitability after a period of elevated R&D and acquisition-related expenses. The balance sheet is leveraged but cash-generative; the debt-to-equity ratio is a negative -21.12 due to accounting treatment of equity, but more importantly, the company generated strong free cash flow of $18.70 billion on a TTM basis. The current ratio of 0.67 indicates relatively low liquidity, which is common for pharma companies that carry significant debt for strategic acquisitions, but the substantial free cash flow provides ample capacity to fund dividends, share repurchases, and business development.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given a positive net income of $1.82 billion in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 96.41x, while the forward P/E is significantly lower at 13.32x; this massive gap implies the market expects a substantial earnings recovery and normalization in the coming year, pricing in the transition past near-term profitability headwinds. Compared to industry averages, AbbVie's forward P/E of 13.32x is difficult to benchmark precisely without a provided sector average, but its price-to-sales ratio of 6.65x and EV/EBITDA of 26.70x suggest a premium valuation relative to many mature pharma peers, which is likely justified by its superior growth profile from the immunology franchise and promising pipeline in neuroscience and oncology. Historically, the stock's own trailing P/E has been highly volatile, ranging from negative figures in recent quarters to 96.41x currently; this places it near the upper end of its recent historical band, reflecting the market's anticipation of a sharp earnings rebound. The current PS ratio of 6.65x is below the historical high of 27.76x seen in Q1 2025, suggesting that while earnings multiples are stretched, the sales multiple does not indicate extreme overvaluation relative to its own history.
PE
96.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's financial risk profile is mixed. While TTM free cash flow of $18.70 billion is robust, the company operates with relatively low liquidity, evidenced by a current ratio of 0.67. Profitability has been volatile, with Q4 2025 net income of $1.82 billion rebounding sharply from $186 million in Q3, but the trailing P/E of 96.41x indicates earnings are depressed, creating valuation risk if the recovery stalls. Revenue, though growing at 10.04% YoY, remains concentrated in immunology (Skyrizi and Rinvoq), creating dependency on these two products to offset Humira's decline and fend off new competitors like J&J's Icotyde.
Market & Competitive Risks: The stock trades at a premium valuation with a PS ratio of 6.65x and EV/EBITDA of 26.70x, making it vulnerable to multiple compression if growth expectations are not met. Competitive disruption is a material threat, as recent FDA approvals for rival drugs in psoriasis and chronic lymphocytic leukemia directly challenge AbbVie's core franchises. The stock's low beta of 0.309 suggests it is not highly sensitive to broad market swings, but it has shown significant company-specific volatility, with a max drawdown of -19.23% and recent underperformance versus the SPY by 9.57% over three months, indicating investor concern over these company-specific issues.
Worst-Case Scenario: The most damaging scenario would involve a combination of Skyrizi/Rinvoq growth decelerating faster than expected due to intensified competition, coupled with pipeline setbacks in obesity or neuroscience and a broader sector de-rating. This could trigger analyst downgrades and a re-rating to a lower sales multiple. The realistic downside could see the stock re-testing its 52-week low of $181.73, representing a potential loss of approximately -16% from the current price of ~$216.49. A breach of that support could lead to further declines toward the $170-$175 range, aligning with a bear-case target implied by a significant compression in the forward P/E multiple.
FAQ
The key risks are: 1) Valuation Risk: The premium sales and EBITDA multiples could compress if growth decelerates. 2) Competitive Risk: New drugs like J&J's oral psoriasis pill Icotyde threaten the growth trajectory of blockbuster Skyrizi. 3) Execution Risk: The company must successfully integrate recent acquisitions (Cerevel, ImmunoGen) and advance its pipeline, as seen with the recent FDA manufacturing rejection for TrenibotE. 4) Financial Risk: While cash flow is strong, the low current ratio (0.67) indicates tight liquidity, and the company carries significant debt from its acquisition strategy.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $225 and $240 as the company executes its transition, supported by analyst EPS estimates around $20.11. The Bull Case (30% probability) targets a breakout above the 52-week high of $244.81 toward $260, driven by outperforming growth and pipeline successes. The Bear Case (15% probability) warns of a decline to the $181.73 - $200 range if competition intensifies or earnings disappoint. The most likely outcome is the Base Case, contingent on AbbVie delivering consistent quarterly results that validate its forward earnings multiple.
ABBV sends mixed valuation signals. Its trailing P/E of 96.41x is misleadingly high due to depressed recent earnings, but its forward P/E of 13.32x suggests the market expects significant profit normalization. The price-to-sales ratio of 6.65x and EV/EBITDA of 26.70x indicate a premium valuation relative to many mature pharmaceutical peers. This premium is likely justified by its superior growth profile from Skyrizi and Rinvoq. Overall, the stock is fairly valued to slightly overvalued, as the market is already pricing in a successful execution of its growth transition.
ABBV is a Hold, not a clear-cut buy at current levels. For income-focused, long-term investors, its strong cash flow and reliable dividend are attractive, and the forward P/E of 13.32x is reasonable if earnings recover as expected. However, the recent technical downtrend, premium sales multiple (PS 6.65x), and competitive threats create near-term risk. It would become a more compelling buy on a pullback closer to $200 or on a confirmed technical breakout above $245, which would signal renewed institutional confidence.
ABBV is primarily suitable for a long-term investment horizon of 3-5 years. Its low beta (0.309) and dividend make it a stable holding, but the current transition story requires time to fully play out as Skyrizi and Rinvoq mature and new pipeline assets develop. Short-term trading is challenged by the stock's recent downtrend and lack of clear directional momentum. Investors should be prepared to hold through potential volatility to capture the dividend and benefit from the long-term growth of its diversified portfolio.